Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18081793 | 0.83 | KDM4E (0.35) | KDM4EALDH1A1HPGDRAB9AGFER | |
| SCHEMBL18081806 | 0.83 | RAB9A (0.33) | KDM4EALDH1A1HPGDRAB9AGFER | |
| SCHEMBL18081970 | 0.83 | RAB9A (0.31) | KDM4EALDH1A1HPGDRAB9AGFER | |
| SCHEMBL18080562 | 0.82 | CHEK1 (0.30) | — | |
| SCHEMBL18081797 | 0.76 | RAB9A (0.31) | KDM4EALDH1A1HPGDRAB9AGFER | |
| SCHEMBL16631750 | 0.74 | HTT (0.33) | KDM4EALDH1A1HPGDHTT | |
| SCHEMBL16631767 | 0.74 | MAPK1 (0.34) | KDM4EALDH1A1HPGDRAB9ANPC1 | |
| SCHEMBL18080564 | 0.73 | KDM4E (0.31) | KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL18081975 | 0.71 | ALDH1A1 (0.45) | KDM4EALDH1A1HPGDRAB9AGFER | |
| SCHEMBL16631921 | 0.69 | KDM4E (0.36) | KDM4EALDH1A1HPGDRAB9AGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2015051173-A2 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | POLRMT, POLN, NSUN3 | KDM4E 4689/4885ALDH1A1 4189/4885HPGD 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.